Home | Welcome to Contract Pharma   
Last Updated Tuesday, June 18 2013
Print RSS Feed

Breaking News

Related Searches:
Covance 3Q

October 25, 2007
Covance 3Q Revenues: $415 mlllion (+16%) 3Q Earnings: $45 million (+17%) YTD Revenues: $1.2 billion (+14%) YTD Earnings: $125 million (+17%) Comments: Early development results were up 19% to $200 million, while late-stage services ros…  Read More »
Amgen 3Q

October 25, 2007
Amgen 3Q Revenues: $3.6 billion (flat) 3Q Earnings: $201 million (-81%) YTD Revenues: $11.0 billion (+6%) YTD Earnings: $2.3 billion (+10%) Comments: Overall U.S. sales diminished 2% as Medicare reimbursement for Aranesp was lowered, w…  Read More »
PPD Opens New International Offices

October 24, 2007
PPD, Inc. has opened offices in Sydney, Australia; Copenhagen, Denmark; Lisbon, Portugal; and Lima, Peru. The company says the moves reflect "continued expansion of its Phase II-IV services in key therapeutic areas." The four new offices…  Read More »
Genzyme 3Q

October 24, 2007
Genzyme Corp. 3Q Revenues: $960 million (+19%) 3Q Earnings: $159 million (up from $16 million in 3Q06) YTD Revenues: $2.8 billion (+19%) YTD Earnings: $401 million (+60%) Comments: Myzozyme sales rose 162% to $54 million in 3Q07, and t…  Read More »
GlaxoSmithKline 3Q

October 24, 2007
GlaxoSmithKline 3Q Revenues: $11.1 billion (+5% in USD, -3% in local currency) 3Q Earnings: $2.7 billion (+2% in USD, -6% in local currency) YTD Revenues: $33.3 billion (+6% in USD, -3% in local currency) YTD Earnings: $8.4 billion (+8% i…  Read More »
Almac Invests $100 million in NA HQ

October 23, 2007
Almac, a provider of R&D and manufacturing services based in Craigavon, Northern Ireland, announced plans to invest $100 million to build its North American headquarters. The new facility will add approximately 260 jobs within three years. Sai…  Read More »
GSK, Tolerx Collaborate on Anti-CD3 MAb

October 23, 2007
GlaxoSmithKline and Tolerx, Inc. have formed a worldwide alliance to develop and commercialize otelixizumab (TRX4), a novel humanized anti-CD3 monoclonal antibody that has potential across a broad range of autoimmune and immune-mediated inflammatory…  Read More »
Biogen Idec 3Q

October 23, 2007
Biogen Idec 3Q Revenues: $789 million (+12%) 3Q Earnings: $119 million (-24%) YTD Revenues: $2.3 billion (+15%) YTD Earnings: $437 million (+301%) Comments: Avonex sales leveled off, up 2% to $455 million, while BI's share of Rituxan r…  Read More »
Merck 3Q

October 22, 2007
Merck 3Q Revenues: $6.1 billion (+12%) 3Q Earnings: $1.5 billion (+62%) YTD Revenues: $18.0 billion (+8%) YTD Earnings: $4.9 billion (+24%) Comments: Singulair sales rose 17% to $1 billion. Diabetes treatment Januvia, launched in Octob…  Read More »
Schering-Plough 3Q

October 22, 2007
Schering-Plough 3Q Revenues: $2.8 billion (+9%) 3Q Earnings: $750 million (+142%) YTD Revenues: $9.0 billion (+13%) YTD Earnings: $1.9 billion (+97%) Comments: Revenues do not reflect sales of Vytorin and Zetia, which are accounted as…  Read More »
Phase II TRA Results for Schering-Plough

October 22, 2007
Schering-Plough released not-bad news about its novel oral thrombin receptor antagonist (TRA), as two Phase II studies in patients with vascular disease showed that TRA does not increase the rate of major or minor bleeding in patients with acute coro…  Read More »
Gilead Sciences 3Q

October 19, 2007
Gilead Sciences 3Q Revenues: $1.1 billion (+41%) 3Q Earnings: $398 million (net loss of $52 million in 3Q06) YTD Revenues: $3.1 billion (+47%) YTD Earnings: $1.2 billion (+155%) Comments: Sales of new HIV medication Atripla reached $24…  Read More »
King Pharma Changes Strategy, Lays Off 20%

October 19, 2007
King Pharmaceuticals plans to lay off 20% of its workforce in an effort to speed up its strategic focus in neuroscience and hospital/acute care. The company estimates that the firings and other reductions in general and administrative expenses will s…  Read More »
Pfizer 3Q

October 18, 2007
Pfizer 3Q Revenues: $12.0 billion (-2%) 3Q Earnings: $761 million (-77%) YTD Revenues: $35.6 billion (-1%) YTD Earnings: $5.4 billion (-45%) Comments: 3Q Pharma sales dropped 4% to $11.0 billion. Ongoing generic erosion from Zoloft (Ju…  Read More »
Wyeth 3Q

October 18, 2007
Wyeth 3Q Revenues: $5.6 billion (+9%) 3Q Earnings: $1.1 billion (flat) YTD Revenues: $16.6 billion (+10%) YTD Earnings: $3.6 billion (+8%) Comments: 3Q pharma revenues were up 10% to $4.7 billion, driven by a 24% boost in sales of Prev…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: